Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

BACKGROUND: Anti-drug antibodies (ADAs) to bococizumab were detected in > 40% of subjects in the SPIRE lipid-lowering trials. The risk of cross-reactivity between anti-bococizumab antibodies and other approved anti-proprotein convertase subtilisin/kexin type-9 (PCSK9) monoclonal antibodies (mAbs)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Ellen Q., Bukowski, Jack F., Yunis, Carla, Shear, Charles L., Ridker, Paul M., Schwartz, Pamela F., Baltrukonis, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790354/
https://www.ncbi.nlm.nih.gov/pubmed/31529318
http://dx.doi.org/10.1007/s40259-019-00375-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790354/
https://www.ncbi.nlm.nih.gov/pubmed/31529318
http://dx.doi.org/10.1007/s40259-019-00375-0

Ejemplares similares